10x Genomics (TXG) Share-based Compensation (2018 - 2026)

10x Genomics has reported Share-based Compensation for 9 years, with the latest figure at $22.6 million in Q1 2026.

• Quarterly Share-based Compensation fell 27.14% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 158.64% YoY) and the FY2025 annual result came in at $11.4 million, changed N/A from the prior year.
• Share-based Compensation grew to $22.6 million in Q1 2026 per TXG's latest filing, from -$72.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $159.8 million in Q4 2023 and troughed at -$108.2 million in Q4 2024.
• A 5-year average of $14.5 million and a median of $22.6 million in 2026 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 271.2% in 2023, then soared 38964.62% in 2024.
• Over 5 years, Share-based Compensation stood at -$9.5 million in 2022, then jumped by 1784.55% to $159.8 million in 2023, then plunged by 167.72% to -$108.2 million in 2024, then surged by 33.0% to -$72.5 million in 2025, then soared by 131.23% to $22.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $22.6 million, -$72.5 million, and $75.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.